Observational

COVID-19 in Patients with HIV

Investigator: Debra Powell, MD

The purpose of his study is to characterize the clinical presentation and course of COVID-19 in patients with HIV.

Learn more about the COVID HIV trial or call the Clinical Trials Office at 484-628-8585.


Treatment

IMPACC

"Immunophenotyping Assessment in a COVID-19 COHORT"

Investigator: Debra Powell, MD

The purpose of this observational study is to describe the relationship between the body's immune responses and the severity of COVID-19 in patients.

Learn more about the IMPACC trial.

View on NIH.gov and ClinicalTrials.gov, or call the Clinical Trials Office at 484-628-8585 for more information.


CAN-COVID

"Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants with COVID-19-induced Pneumonia"

Investigator: Debra Powell, MD

The purpose of this study is to to assess the efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC in patients with COVID-19-induced pneumonia and cytokine release syndrome (CRS). This study is closed to enrollment.

Learn more about the CAN-COVID trial.

View on Novartis and ClinicalTrials.gov, or call the Clinical Trials Office at 484-628-8585 for more information.


Convalescent Plasma

"Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19"

Investigator: Debra Powell, MD

The purpose of this treatment plan is to provide access to investigational convalescent plasma for patients in acute care facilities infected with COVID-19. Plasma will be obtained from donors with a documented diagnosis of COVID-19 that have recovered from the infection.

Learn more about the Convalescent Plasma treatment.

View on RedCrossBlood.org and USCOVIDPlasma.org, or call the Clinical Trials Office at 484-628-8585 for more information.